Login / Signup

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial.

Uwe ReuterChristian LucasDavid DolezilAustin L HandMartha D PortRussell M NicholsChad StroudAntje Tockhorn-HeidenreichHolland C Detke
Published in: Advances in therapy (2021)
ClinicalTrials.gov identifier NCT03559257.
Keyphrases
  • open label
  • phase iii
  • phase ii
  • study protocol
  • clinical trial
  • phase ii study
  • healthcare
  • randomized controlled trial
  • adverse drug
  • double blind
  • squamous cell carcinoma
  • emergency department